Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes in Patients with Acute Coronary Syndrome and Type 2 Diabetes.
鈉-葡萄糖共轉運蛋白 2 抑制劑對急性冠狀動脈綜合症及 2 型糖尿病患者心血管結果的影響。
Diabetes Metab Syndr Obes 2024-11-27
Sodium-Glucose Cotransporter 2 Inhibitors Improve Body Composition by Increasing the Skeletal Muscle Mass/Fat Mass Ratio in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study.
鈉-葡萄糖共轉運蛋白 2 抑制劑透過增加骨骼肌質量/脂肪質量比改善 2 型糖尿病患者的身體組成:一項 52 週的前瞻性實際研究。
Nutrients 2024-11-27
Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Heart Failure: An Update.
心衰竭糖尿病患者中鈉-葡萄糖共轉運蛋白-2抑制劑的最新進展。
Pharmaceuticals (Basel) 2024-11-27
Glucometabolic Efficacy of the Empagliflozin/Metformin Combination in People with Type 1 Diabetes and Increased Cardiovascular Risk: A Sub-Analysis of a Pilot Randomized Controlled Trial.
Empagliflozin/Metformin 组合在1型糖尿病及心血管风险增加人群中的葡萄糖代谢疗效:一项初步随机对照试验的子分析。
J Clin Med 2024-11-27
Proteinuria and Progression of Renal Damage: The Main Pathogenetic Mechanisms and Pharmacological Approach.
蛋白尿與腎損傷進展:主要的病理生理機制及藥物治療方法。
Medicina (Kaunas) 2024-11-27
The Potential Impact of SGLT2-I in Diabetic Foot Prevention: Promising Pathophysiologic Implications, State of the Art, and Future Perspectives-A Narrative Review.
SGLT2-I 在糖尿病足預防中的潛在影響:有前景的病理生理意涵、最新進展及未來展望 - 敘述性綜述。
Medicina (Kaunas) 2024-11-27